Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant sintilimab plus chemotherapy followed by surgery vs concurrent chemoradiotherapy in limited-stage SCLC
ChiCTR2600129772Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of sintilimab in small cell lung cancer (SCLC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Event-free survival (EFS). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600129772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129772.